Solid Biosciences (NASDAQ:SLDB) had its target price decreased by Nomura from $52.00 to $37.00 in a research report sent to investors on Monday, March 19th. Nomura currently has a buy rating on the stock.
Several other brokerages have also weighed in on SLDB. Leerink Swann started coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued an outperform rating and a $36.00 price objective for the company. JPMorgan Chase started coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued a neutral rating and a $28.00 price objective for the company. Instinet started coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued a buy rating and a $52.00 price objective for the company. Chardan Capital started coverage on Solid Biosciences in a report on Wednesday, February 21st. They issued a buy rating and a $40.00 price objective for the company. Finally, Goldman Sachs started coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued a neutral rating and a $31.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $33.67.
Shares of Solid Biosciences stock traded up $0.02 during trading hours on Monday, hitting $10.07. 180,231 shares of the company’s stock traded hands, compared to its average volume of 395,608. Solid Biosciences has a 12-month low of $6.83 and a 12-month high of $33.74. The firm has a market cap of $353.70 and a PE ratio of -3.50.
In related news, Director Life Sciences Maste Perceptive bought 1,020,000 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was acquired at an average price of $16.22 per share, for a total transaction of $16,544,400.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
WARNING: This report was published by Macon Daily and is owned by of Macon Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://macondaily.com/2018/04/12/nomura-lowers-solid-biosciences-sldb-price-target-to-37-00-updated-updated-updated.html.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.